These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 15933740)
1. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Bar J; Lukaschuk N; Zalcenstein A; Wilder S; Seger R; Oren M Cell Death Differ; 2005 Dec; 12(12):1578-87. PubMed ID: 15933740 [TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. Badinloo M; Esmaeili-Mahani S Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575 [TBL] [Abstract][Full Text] [Related]
3. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663 [TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052 [TBL] [Abstract][Full Text] [Related]
5. LY294002, an inhibitor of PI-3K, enhances heat sensitivity independently of p53 status in human lung cancer cells. Ohnishi K; Yasumoto J; Takahashi A; Ohnishi T Int J Oncol; 2006 Jul; 29(1):249-53. PubMed ID: 16773206 [TBL] [Abstract][Full Text] [Related]
6. LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells. Xing CG; Zhu BS; Liu HH; Lin F; Yao HH; Liang ZQ; Qin ZH Acta Pharmacol Sin; 2008 Apr; 29(4):489-98. PubMed ID: 18358096 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Fujiwara Y; Kawada K; Takano D; Tanimura S; Ozaki K; Kohno M Biochem Biophys Res Commun; 2006 Feb; 340(2):560-6. PubMed ID: 16378598 [TBL] [Abstract][Full Text] [Related]
8. The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. Mallawaaratchy DM; Mactier S; Kaufman KL; Blomfield K; Christopherson RI J Proteomics; 2012 Feb; 75(5):1590-9. PubMed ID: 22172953 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Zheng L; Ren JQ; Li H; Kong ZL; Zhu HG Cell Res; 2004 Dec; 14(6):497-506. PubMed ID: 15625017 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387 [TBL] [Abstract][Full Text] [Related]
11. Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901. Xing C; Zhu B; Liu H; Yao H; Zhang L Acta Biochim Biophys Sin (Shanghai); 2008 Mar; 40(3):194-201. PubMed ID: 18330473 [TBL] [Abstract][Full Text] [Related]
12. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465 [TBL] [Abstract][Full Text] [Related]
13. Beta-sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells. Moon DO; Lee KJ; Choi YH; Kim GY Int Immunopharmacol; 2007 Aug; 7(8):1044-53. PubMed ID: 17570321 [TBL] [Abstract][Full Text] [Related]
14. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569 [TBL] [Abstract][Full Text] [Related]
15. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Lane D; Robert V; Grondin R; Rancourt C; Piché A Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321 [TBL] [Abstract][Full Text] [Related]
17. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7]. Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518 [TBL] [Abstract][Full Text] [Related]
18. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Kunnimalaiyaan M; Ndiaye M; Chen H Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151 [TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 prevents Abeta[25-35]/(H2O2)- induced apoptosis in lymphocytes by reciprocal NF-kappaB activation and p53 inhibition via PI3K-dependent pathway. Jimenez Del Rio M; Velez-Pardo C Growth Factors; 2006 Mar; 24(1):67-78. PubMed ID: 16393695 [TBL] [Abstract][Full Text] [Related]
20. DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. Watanabe M; Naraba H; Sakyo T; Kitagawa T Mol Cancer Res; 2010 Nov; 8(11):1547-57. PubMed ID: 20870738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]